Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

  • End date
    Jul 31, 2022
  • participants needed
  • sponsor
    University of Rochester
Updated on 8 August 2021
chemotherapy regimen


The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.


This is an open label, phase 2 study consisting of daratumumab, lenalidomide and dexamethasone, given upfront in newly diagnosed, transplant ineligible patients with myeloma. Patients participating in the study will be recruited from the Wilmot Cancer Institute, University of Rochester in Rochester, New York and all University of Rochester community affiliates.

Patients will be treated with 1800 milligrams of Daratumumab subcutaneously or 16 milligrams/kilograms daratumumab intravenously (IV) weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks. Patients will be treated with 25 milligrams of Lenalidomide days 1-21 out of a 28 day cycle (dose adjustments for creatinine clearance) and 20 milligrams of Dexamethasone at least 60 minutes prior to first infusion of daratumumab. Each cycle consists of 28 days (4 weeks).

Response assessments by International Myeloma Working Group criteria for myeloma will be performed every 4 weeks while on therapy.

Condition Multiple Myeloma, Lymphoproliferative Disorder, multiple myeloma (mm)
Treatment Dexamethasone, Lenalidomide, Daratumumab
Clinical Study IdentifierNCT04635189
SponsorUniversity of Rochester
Last Modified on8 August 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of multiple myeloma with diagnosis
Must not have received previous therapy for multiple myeloma
Newly diagnosed and not considered candidate for high-dose chemotherapy
Adequate organ system function
A performance status 3
Ability to swallow and retain oral medication
Female subjects of child bearing potential must be surgically sterile, be post-menopausal

Exclusion Criteria

A diagnosis of primary amyloidosis; monoclonal gammopathy of undetermined significance, smoldering multiple myeloma; non-secretory myeloma
A diagnosis of Waldenstrm's disease
Receiving cancer therapy
Radiation therapy within 14 days of enrollment
Major surgery within 2 weeks before enrollment
Human immunodeficiency virus -infected patients must be on effective anti-retroviral therapy with undetectable viral load within the past 6 months
Seropositive for hepatitis B, or seropositive for hepatitis C
Ongoing systemic bacterial, fungal or viral infection
Severe and/or uncontrolled medical conditions
Malignancy within 2 years of study enrollment
Women who are pregnant or lactating
Contraindications to required prophylaxis for deep vein thrombosis and pulmonary embolism
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note